Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 11 (November)

1. Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole.
   Ann Pharmacother, 40(11): 2059-63. [Abstract] [Full-text]
2. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
   Transfusion, 46(11): 1886-91. [Abstract] [Full-text]
3. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis.
   J Hepatol, 45(6): 844-50. [Abstract] [Full-text]
4. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma.
   J Hepatol, 45(6): 805-12. [Abstract] [Full-text]
5. Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.
   J Hepatol, 45(6): 779-85. [Abstract] [Full-text]
6. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV.
   J Hepatol, 45(6): 770-8. [Abstract] [Full-text]
7. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C.
   Liver Transpl, 12(11): 1673-81. [Abstract] [Full-text]
8. Pseudo-outbreak of hepatitis B virus infection associated with contamination of a semiautomatic cap remover.
   Infect Control Hosp Epidemiol, 27(11): 1258-60. [Abstract] [Full-text]
9. Seroprevalence survey of varicella, measles, rubella, and hepatitis A and B viruses in a multinational healthcare workforce in Saudi Arabia.
   Infect Control Hosp Epidemiol, 27(11): 1178-83. [Abstract] [Full-text]
10. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection.
    J Clin Invest, 116(11): 3006-14. [Abstract] [Full-text]
11. Possible compartmentalization of hepatitis C viral replication in the genital tract of HIV-1-coinfected women.
    J Infect Dis, 194(11): 1529-36. [Abstract] [Full-text]
12. Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems.
    J Subst Abuse Treat, 31(4): 411-7. [Abstract] [Full-text]
13. Illness-related stigma, mood and adjustment to illness in persons with hepatitis C.
    Soc Sci Med, 63(12): 3188-98. [Abstract] [Full-text]
14. Granulomatous hepatitis and Sjogren's syndrome: an association.
    Semin Arthritis Rheum, 36(3): 153-8. [Abstract] [Full-text]
15. Comparison of real-time reverse transcriptase-polymerase chain reaction and nested or commercial reverse transcriptase-polymerase chain reaction for the detection of hepatitis E virus particle in human serum.
    Diagn Microbiol Infect Dis, 56(3): 269-74. [Abstract] [Full-text]
16. Lipid peroxidation and serum cytokines in acute alcoholic hepatitis.
    Alcohol Alcohol, 41(6): 593-7. [Abstract] [Full-text]
17. Not polymorphism but methylation of class II transactivator gene promoter IV associated with persistent HBV infection.
    J Clin Virol, 37(4): 282-6. [Abstract] [Full-text]
18. Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment.
    J Clin Virol, 37(4): 329-31. [Abstract] [Full-text]
19. Steatosis in hepatitis C: the missing link to metabolic abnormalities?
    Am J Gastroenterol, 101(11): 2616-8. [Abstract] [Full-text]
20. Liver steatosis in children with chronic hepatitis C.
    Am J Gastroenterol, 101(11): 2611-5. [Abstract] [Full-text]
21. Replication of a hepatitis C virus replicon clone in mouse cells.
    Virol J, 3: 89. [Abstract] [Full-text]
22. Evidence of recombination in quasispecies populations of a Hepatitis C Virus patient undergoing anti-viral therapy.
    Virol J, 3: 87. [Abstract] [Full-text]
23. Epidemiological and virological features of HBV infection in HIV-2 infected patients living in southeastern France.
    Eur J Epidemiol, 21(8): 615-8. [Abstract] [Full-text]
24. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease.
    Am J Gastroenterol, 101(11): 2537-45. [Abstract] [Full-text]
25. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
    Am J Gastroenterol, 101(11): 2523-9. [Abstract] [Full-text]
26. Molecular epidemiology of hepatitis A virus in metropolitan areas in Japan.
    J Gastroenterol, 41(10): 981-6. [Abstract] [Full-text]
27. High levels of hepatitis B virus DNA in body fluids from chronic carriers.
    J Hosp Infect, 64(4): 352-7. [Abstract] [Full-text]
28. Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects.
    Microbes Infect, 8(12): 2783-90. [Abstract] [Full-text]
29. Eosinophilic granulomatous gastroenterocolitis and hepatitis in a 1-year-old male Siberian Husky.
    Vet Pathol, 43(6): 1022-5. [Abstract] [Full-text]
30. Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm.
    Transplant Proc, 38(8): 2675-6. [Abstract] [Full-text]
31. Scarce influence of corticosteroid boluses on long-term viral load and liver histology in transplanted patients with recurrent hepatitis C.
    Transplant Proc, 38(8): 2502-4. [Abstract] [Full-text]
32. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology.
    Transplant Proc, 38(8): 2499-501. [Abstract] [Full-text]
33. Hepatitis B virus among schoolchildren in an endemic area in Egypt over a decade: impact of hepatitis B vaccine.
    Am J Infect Control, 34(9): 600-2. [Abstract] [Full-text]
34. Hepatitis B immunoglobulin in combination with lamivudine for prevention of hepatitis B virus reactivation in children undergoing bone marrow transplantation.
    Pediatr Transplant, 10(8): 966-9. [Abstract] [Full-text]
35. A temporal study on the histopathological, biochemical and molecular responses of CCl(4)-induced hepatotoxicity in Cyp2e1-null mice.
    Toxicology, 228(2): 310-22. [Abstract] [Full-text]
36. Serum neopterin levels in patients with replicative and nonreplicative HBV carriers.
    BMC Infect Dis, 6: 157. [Abstract] [Full-text]
37. Hepatitis B infection among health workers in Uganda: evidence of the need for health worker protection.
    Vaccine, 24(47): 6930-7. [Abstract] [Full-text]
38. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
    Vaccine, 24(49): 7167-74. [Abstract] [Full-text]
39. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects.
    Vaccine, 24(49): 7124-8. [Abstract] [Full-text]
40. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever.
    Vaccine, 24(49): 7181-9. [Abstract] [Full-text]
41. Advice from a medical expert through the Internet on queries about AIDS and hepatitis: analysis of a pilot experiment.
    PLoS Med, 3(7): e256. [Abstract] [Full-text]
42. Follow-up for medical care among drug users with hepatitis C.
    Eval Health Prof, 29(4): 355-66. [Abstract] [Full-text]
43. Serum C-reactive protein: a non-invasive marker of alcoholic hepatitis.
    Scand J Gastroenterol, 41(12): 1473-9. [Abstract] [Full-text]
44. Hepatocellular carcinoma with sarcomatous change arising after eradication of HCV via interferon therapy.
    Clin Imaging, 30(6): 416-9. [Abstract] [Full-text]
45. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection.
    Gastroenterology, 131(5): 1584-91. [Abstract] [Full-text]
46. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
    Gastroenterology, 131(5): 1440-51. [Abstract] [Full-text]
47. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Clin Transplant, 20(6): 677-83. [Abstract] [Full-text]
48. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient.
    Am J Hematol, 81(12): 969-72. [Abstract] [Full-text]
49. Hepatitis C virus infection among First Nation and non-First Nation people in Manitoba, Canada: a public health laboratory study.
    Can J Microbiol, 52(10): 999-1005. [Abstract] [Full-text]
50. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C.
    J Viral Hepat, 13(12): 845-50. [Abstract] [Full-text]
51. Molecular detection and sequence analysis of a new hepatitis E virus isolate from Pakistan.
    J Viral Hepat, 13(12): 840-4. [Abstract] [Full-text]
52. Quantitative detection of hepatitis E virus RNA and dynamics of viral replication in experimental infection.
    J Viral Hepat, 13(12): 835-9. [Abstract] [Full-text]
53. Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels.
    J Viral Hepat, 13(12): 828-34. [Abstract] [Full-text]
54. Alpha-defensin increase in peripheral blood mononuclear cells from patients with hepatitis C virus chronic infection.
    J Viral Hepat, 13(12): 821-7. [Abstract] [Full-text]
55. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
    J Viral Hepat, 13(12): 811-20. [Abstract] [Full-text]
56. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus.
    J Viral Hepat, 13(12): 799-810. [Abstract] [Full-text]
57. Chronic hepatitis B: current epidemiology in the Americas and implications for management.
    J Viral Hepat, 13(12): 787-98. [Abstract] [Full-text]
58. A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes.
    J Infect Dis, 194(12): 1724-8. [Abstract] [Full-text]
59. Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo.
    J Infect Dis, 194(12): 1713-23. [Abstract] [Full-text]
60. Antiviral treatment of hepatitis C: present status and future prospects.
    J Infect Chemother, 12(5): 227-32. [Abstract] [Full-text]
61. Risk of exposure to hepatitis B and other blood-borne viruses among Australians who travel abroad.
    J Travel Med, 13(6): 345-50. [Abstract] [Full-text]
62. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.
    Liver Int, 26(10): 1294-7. [Abstract] [Full-text]
63. Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis.
    Liver Int, 26(10): 1201-8. [Abstract] [Full-text]
64. A single alcohol ingestion does not affect serum hepatitis C virus RNA in patients with chronic hepatitis C.
    Liver Int, 26(10): 1196-200. [Abstract] [Full-text]
65. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
    Liver Int, 26(10): 1187-95. [Abstract] [Full-text]
66. Targets of emerging therapies for viral hepatitis B and C.
    Expert Opin Ther Targets, 10(6): 833-50. [Abstract] [Full-text]
67. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia.
    Eur J Haematol, 77(6): 513-7. [Abstract] [Full-text]
68. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1.
    J Clin Immunol, 26(6): 495-505. [Abstract] [Full-text]
69. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation.
    J Pharmacol Exp Ther, 319(3): 1191-9. [Abstract] [Full-text]
70. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives.
    J Pharmacol Exp Ther, 319(3): 1413-23. [Abstract] [Full-text]
71. Estimated incidence of hepatitis A virus infection in Catalonia.
    Ann Epidemiol, 16(11): 812-9. [Abstract] [Full-text]
72. Lamivudine reverses severe acute hepatitis B and pancytopenia after renal transplantation: a case report.
    Transplant Proc, 38(9): 3125-7. [Abstract] [Full-text]
73. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results.
    Transplant Proc, 38(9): 3118-20. [Abstract] [Full-text]
74. New-onset diabetes mellitus after living donor liver transplantation: possible association with hepatitis C.
    Transplant Proc, 38(9): 2989-92. [Abstract] [Full-text]
75. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
    Transplant Proc, 38(9): 2964-7. [Abstract] [Full-text]
76. Toxicoproteomics in liver injury and inflammation.
    Ann N Y Acad Sci, 1076: 707-17. [Abstract] [Full-text]
77. Hepatitis C and arthritis: an update.
    Infect Dis Clin North Am, 20(4): 877-89, vii. [Abstract] [Full-text]
78. Hepatitis C in people with mental illness: how big is the problem and how do we respond?
    Australas Psychiatry, 14(4): 374-8. [Abstract] [Full-text]
79. Effects of HCV treatment on cytokine expression during HCV/HIV coinfection.
    J Interferon Cytokine Res, 26(11): 834-8. [Abstract] [Full-text]
80. Serologic indices of hepatitis B virus infection in military recruits in Greece (2004-2005).
    BMC Infect Dis, 6: 163. [Abstract] [Full-text]
81. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.
    BMC Gastroenterol, 6: 34. [Abstract] [Full-text]
82. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection.
    Proc Natl Acad Sci U S A, 103(47): 17862-7. [Abstract] [Full-text]
83. Liver cirrhosis and membranoproliferative glomerulonephritis caused by inapparent hepatitis C virus infection.
    Pathol Res Pract, 202(12): 891-4. [Abstract] [Full-text]
84. Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients.
    Immunogenetics, 58(12): 937-46. [Abstract] [Full-text]
85. Dynamics of a hepatitis B virus e antigen minus population ascribed to genotype F during the course of a chronic infection despite the presence of anti-HBs antibodies.
    Virus Res, 123(1): 72-85. [Abstract] [Full-text]
86. Leukoencephalopathy as a rare complication of hepatitis C infection.
    Neurol Sci, 27(5): 360-3. [Abstract] [Full-text]
87. Histologic, viral, and molecular correlates of dengue fever infection of the liver using highly sensitive immunohistochemistry.
    Diagn Mol Pathol, 15(4): 223-8. [Abstract] [Full-text]
88. Association of interferon-gamma gene haplotype in the Chinese population with hepatitis B virus infection.
    Immunogenetics, 58(11): 859-64. [Abstract] [Full-text]
89. Genetic structural differences between responders and non-responders to interferon therapy for chronic hepatitis-B patients.
    J Hum Genet, 51(11): 984-91. [Abstract] [Full-text]
90. Genome-wide characterisation of hepatitis B mutations involved in clinical outcome.
    Heredity, 97(6): 389-97. [Abstract] [Full-text]
91. Type 1 autoimmune hepatitis in Taiwan: diagnosis using the revised criteria of the International Autoimmune Hepatitis Group.
    Dig Dis Sci, 51(11): 1978-84. [Abstract] [Full-text]
92. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients?
    Dig Dis Sci, 51(11): 1962-6. [Abstract] [Full-text]
93. Recurrent hepatitis C after living donor liver transplantation detected by Tc-99m GSA liver scintigraphy.
    Dig Dis Sci, 51(11): 2013-7. [Abstract] [Full-text]
94. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users.
    Epidemiol Infect, 135(1): 144-50. [Abstract] [Full-text]
95. Influence of various diet regimens on deterioration of hepatic function and hematological parameters following carbon tetrachloride: a potential protective role of natural honey.
    Nat Prod Res, 20(13): 1258-64. [Abstract] [Full-text]
96. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
    Pharmacotherapy, 26(12): 1745-57. [Abstract] [Full-text]
97. Risk factors for hepatitis B infection during pregnancy in a Nigerian obstetric population.
    J Obstet Gynaecol, 26(8): 770-2. [Abstract] [Full-text]
98. Immunogenicity of hepatitis A-inactivated vaccine administered to seronegative infants, and serological follow-up 12 months after second dose.
    Acta Paediatr, 95(12): 1582-5. [Abstract] [Full-text]
99. Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study.
    Br J Cancer, 95(11): 1598-602. [Abstract] [Full-text]
100. A role for IRF3-dependent RXRalpha repression in hepatotoxicity associated with viral infections.
     J Exp Med, 203(12): 2589-602. [Abstract] [Full-text]
101. Hepatitis B treatment: Lessons for the nephrologist.
     Kidney Int, 70(11): 1897-904. [Abstract] [Full-text]
102. Comparison of trip characteristics of children and adults with travel-acquired hepatitis A infection.
     Pediatr Infect Dis J, 25(12): 1184-6. [Abstract] [Full-text]
103. Nonalcoholic fatty liver disease of obesity.
     Obes Surg, 16(11): 1412-9. [Abstract] [Full-text]

© 2006-2010 Hepatitis Research Today. All Rights Reserved.